Printer Friendly

IMMUNEX OPENS NEW MANUFACTURING AND DEVELOPMENT CENTER

 IMMUNEX OPENS NEW MANUFACTURING AND DEVELOPMENT CENTER
 SEATTLE, Oct. 15 /PRNewswire/ -- Immunex Corp. (NASDAQ: IMNX) today


announced the opening of its new pharmaceutical manufacturing and development center in Bothell, Wash. The 100,000-square-foot center is the first full-scale biopharmaceutical manufacturing facility ever constructed in the Pacific Northwest.
 "We salute Immunex for its contribution to significant advances in science and medicine as well as to the growth of biotechnology in Washington state," said Gov. Booth Gardner.
 A new 80,000-square-foot microbial facility, designed by architectural and engineering firm Fluor Daniel of Greenville, S.C., has been designed to produce the company's flagship product LEUKINE(R) (Sargramostim), which is used to speed recovery and improve survival in cancer patients undergoing bone marrow transplantation. The facility will also produce PIXYKINE (PIXY321) which is in human clinical trials to study its ability to alleviate certain side effects of cancer therapy.
 "The opening of this facility reflects our commitment to bring new and important drugs to market to provide substantial health-care benefits to patients," said Immunex President and Chief Operating Officer Michael Kranda.
 An adjacent 20,000-square-foot mammalian cell facility, designed by The Harris Group of Seattle, is already in operation, and will produce Tumor Necrosis Factor (TNF) receptor and Interleukin-1 (IL-1) receptor for clinical trials. TNF receptor is in Phase I human clinical trials to study its ability to inhibit systemic inflammation in response to infection. IL-1 receptor is also being studied clinically in the settings of allergy, arthritis, systemic inflammation and graft versus host disease. Additional studies are planned to test IL-1 receptor in patients with asthma and acute myelogenous leukemia.
 The 25-acre center includes expansion space for additional manufacturing, laboratory and administrative facilities.
 Immunex is a biopharmaceutical company focused on the research, development, manufacture and marketing of products to treat cancer and autoimmune disease.
 -0- 10/15/92
 /CONTACT: Jason Rubin, vice president, Communications, or Valoree Dowell, director, Communications, Immunex, 206-587-0430/
 (IMNX) CO: Immunex Corp. ST: Washington IN: MTC SU:


SC-TM -- SE002 -- 0398 10/15/92 12:00 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 15, 1992
Words:337
Previous Article:ANALYSTS INTERNATIONAL CORPORATION REPORTS RECORD REVENUES AND EARNINGS FOR 1ST QUARTER
Next Article:FRANK E. WALSH, JR. ELECTED TO TYCO'S BOARD OF DIRECTORS
Topics:


Related Articles
IMMUNEX RECEIVES FUSION PROTEIN PATENT
IMMUNEX REPORTS 1991 PROFIT; PRODUCT SALES DRIVE COMPANY'S FIRST PROFITABLE YEAR
TARGETED GENETICS, FRED HUTCHINSON CANCER RESEARCH CENTER RECEIVE APPROVAL TO BEGIN HUMAN GENE THERAPY TRIAL
IMMUNEX STOCKHOLDERS TO RECEIVE FULL MERGER CONSIDERATION
'BIO.BOSS' BOARD GAME MAKES DEBUT AT BIOTECH ANNUAL MEETING; ATTENDEES TO TEST THEMSELVES AGAINST CHALLENGES OF FAST-GROWING INDUSTRY
Immunex Reports Financial Results
ENBREL Study Suggests Six-Month Administration Is Safe
Immunex and Digital Gene Technologies Announce Innovative Research Collaboration
Immunex: New Enbrel(TM) Long-Term Safety Data Presented at the Annual Pan American Congress of Rheumatology Meeting in Montreal
Abgenix and Amgen Clarify Responsibilities for ABX-EGF.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters